CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

Triple-negative breast cancer (TNBC) is an aggressive disease that lacks established markers to direct therapeutic intervention. Thus, these tumors are routinely treated with cytotoxic chemotherapies (e.g., anthracyclines), which can cause severe side effects that impact quality of life. Recent stud...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: McClendon, A. Kathleen, Dean, Jeffry L., Rivadeneira, Dayana B., Yu, Justine E., Reed, Christopher A., Gao, Erhe, Farber, John L., Force, Thomas, Koch, Walter J., Knudsen, Erik S.
Formato: Artigo
Idioma:Inglês
Publicado em: Landes Bioscience 2012
Assuntos:
Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3409014/
https://ncbi.nlm.nih.gov/pubmed/22751436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cc.21127
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados